CMS, an Elekta company and a radiation treatment planning company, has completed internal and external validation testing for its new Atlas-Based Autosegmentation software solution, and has applied to the FDA for 510(k) clearance to distribute the product in the U.S. market.

The CMS Atlas-Based Autosegmentation is a standalone software application that produces estimates of anatomy boundary contours needed to create a radiotherapy treatment plan, according to the St. Louis-based company. CMS said the software is designed with an interface, which communicates with radiotherapy planning programs via DICOM-format data. Editing approximately correct contours takes less time than drawing them fully, giving the user more time to plan a treatment, the company said.

The company also said that the Atlas-Based Autosegmentation uses deformable registration to match the atlas image to corresponding points in a new patient image.